Takeda, Cantel & more: 3 GI company key notes

Here are three updates from gastroenterology companies from the past week:

Advertisement

Takeda’s ulcerative colitis drug Entyvio was one of the key products behind a 4.2 percent increase in underlying revenue. Takeda reported 880.6 billion yen in revenue ($7.82 billion).

Cantel Medical Group appointed Bill Haydon as senior vice president and general manager of the company’s medical division.

The Toronto Stock Exchange approved CRH Medical’s intention to renew its normal course issuer bid.

More articles on gastroenterology:
Study finds advanced adenomas similarly prevalent in white, black populations
West Virginia gastroenterologist sentenced to prison for sexually abusing patients — 5 insights
CRH Medical renews normal course issuer bid — 3 insights

 

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in GI & Endoscopy

  • Birmingham (Ala.) Gastroenterology has opened a clinic in Jasper, Ala., expanding access to digestive health services in the region, the…

  • Premier Health Partners has acquired Dayton, Ohio-based Digestive Specialists, according to a notice posted on the website of law firm…

Advertisement

Comments are closed.